The channel underlying the slow AHP is a therapeutic target for the treatment of cognitive impairment (Disterhoft et al., 1996; Moyer et al., 2000; Power et al., 2001), as the slow AHP amplitude increases with age (Disterhoft et al., 1996; Moyer et al., 2000; Power et al., 2001) and upon acute overexpression of those tau isoforms that are implicated in dementia (Stan et al., 2022). The gene discussed is MAPT; the disease is Cognitive impairment.